Most recipients of allogeneic hematopoietic stem cell transplantation (HSCT) suffer from secondary infertility owing to gonadal damage from myeloablative conditioning. Nevertheless, successful pregnancies have been reported in female HSCT recipients and in female partners of male HSCT recipients.
Most recipients of allogeneic hematopoietic stem cell transplantation (HSCT) suffer from secondary infertility owing to gonadal damage from myeloablative conditioning. Nevertheless, successful pregnancies have been reported in female HSCT recipients and in female partners of male HSCT recipients. 1 These include patients who had conceived via assisted reproductive technologies as well as those who conceived naturally. HSCT recipients are unique in that their red cells and lymphocytes are donor derived. As a result, typical prenatal genetic tests in these patients may be misleading. Here, we report such a case of severe thalassemia detected prenatally on ultrasound in a family, but one of the parental carriers was undetected earlier as a result of a limitation in current screening programs for thalassemia.
A 25-year-old gravida 1, para 0 at 12-week gestation was referred for first-trimester Down screening. The medical records she carried showed that she and her husband had received the free pregestational screening, which included thalassemia and sexually transmitted dis- This was the first undetected fetus with hemoglobin Bart disease we encountered in our experience of using the current prenatal thalassemia screening. Our prenatal screening program for thalassemia begins with a complete blood picture. If maternal MCV is 80 fL or above, we regard the fetus as not being at risk for severe thalassemia and no further assessment was followed. On the other hand, if maternal MCV was found to be low (<80 fL), the partner would be called for blood taking. If the partner's MCV was also low, further testing for α-thalassemia and β-thalassemia would be arranged; if her partner's MCV was normal (>80 fL), we would regard their fetus as not being at risk for severe thalassemia and no further assessment was required.
However, for prenatal thalassemia screening, it is irrelevant to assess the MCV from either the mother or her partner who are HSCT recip- What's already known about this topic?
• Successful pregnancies have been reported in female HSCT recipients and in female partners of male HSCT recipients.
• Most of the time, prenatal genetic screening is performed by testing of blood samples taken from the parents.
What does this study add?
• For HSCT recipients, the hematological and DNA testing results of peripheral blood represent donors' information, and not the information that is passed on to the offspring.
• A medical history record of couples, especially related to a HSCT status, should be specifically requested and implemented into prenatal screening programs.
